Clinical progression and virologic outcomes among study participants using the dapivirine vaginal ring vs. those given a placebo ring were similar, according to a recent trial.
“[This study was performed because] it was considered prudent to follow up those participants with HIV seroconversion in the prevention trials to assess the impact, if any, of dapivirine use on clinical progression and virologic outcomes prior to and after initiation of ART for HIV infection,” John Steytler, MBChB, vice president of pharmacovigilance and clinical development at International Partnership for